PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials

MLA

Francisco Cezar Aquino de Moraes, et al. “PD-1/PD-L1 Inhibitors plus Carboplatin and Paclitaxel Compared with Carboplatin and Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” BMC Cancer, vol. 23, no. 1, Nov. 2023, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s12885-023-11654-z.

APA

Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Lucca Moreira Lopes, Maria Eduarda Cavalcanti Souza, Anna Luíza Soares de Oliveira Rodrigues, Artur Menegaz de Almeida, Carlos Stecca, Marianne Rodrigues Fernandes, & Ney Pereira Carneiro dos Santos. (2023). PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials. BMC Cancer, 23(1), 1–14. https://doi.org/10.1186/s12885-023-11654-z

Chicago

Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Lucca Moreira Lopes, Maria Eduarda Cavalcanti Souza, Anna Luíza Soares de Oliveira Rodrigues, Artur Menegaz de Almeida, Carlos Stecca, Marianne Rodrigues Fernandes, and Ney Pereira Carneiro dos Santos. 2023. “PD-1/PD-L1 Inhibitors plus Carboplatin and Paclitaxel Compared with Carboplatin and Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” BMC Cancer 23 (1): 1–14. doi:10.1186/s12885-023-11654-z.